Literature DB >> 9324181

A review of enzyme induction of warfarin metabolism with recommendations for patient management.

J S Cropp1, H I Bussey.   

Abstract

We conducted a review of literature from the MEDLINE data base (1966-January 1997), and bibliographies of published articles, reviews, and letters to classify enzyme induction of warfarin metabolism interactions by onset, extent, and offset. Ten hepatic microsomal enzyme agents were assessed. Likelihood of interaction was based on the strength of supporting literature. Enzyme induction of warfarin metabolism by rifampin and barbiturates is considered likely, although the characteristics of the interactions are different. An interaction is probable with carbamazepine, griseofulvin, aminoglutethimide, nafcillin, and dicloxacillin. A suspected interaction may occur with smoking and long-term alcohol consumption. Ingestion of a small amount of alcohol is unlikely to interact with warfarin. The effect of phenytoin on warfarin metabolism is unpredictable. Anticipation of the expected time course and extent of interaction may allow for better therapeutic decisions and decrease the chance of inappropriate anticoagulation with its potential for complications.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9324181

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  25 in total

1.  Genetic warfarin dosing: tables versus algorithms.

Authors:  Brian S Finkelman; Brian F Gage; Julie A Johnson; Colleen M Brensinger; Stephen E Kimmel
Journal:  J Am Coll Cardiol       Date:  2011-02-01       Impact factor: 24.094

Review 2.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Effect of gefitinib on warfarin antithrombotic activity.

Authors:  Susumu Arai; Hisashi Mitsufuji; Yasuto Nishii; Sayaka Onoda; Shinichiro Ryuge; Mayuko Wada; Ken Katono; Maiko Iwasaki; Akira Takakura; Sakiko Otani; Michiko Yamamoto; Tomoko Yanaihara; Masanori Yokoba; Masaru Kubota; Masato Katagiri; Tomoya Fukui; Hirosuke Kobayashi; Nobuo Yanase; Ryuji Hataishi; Noriyuki Masuda
Journal:  Int J Clin Oncol       Date:  2009-08-25       Impact factor: 3.402

4.  Dosage individualization of warfarin using artificial neural networks.

Authors:  Mohammad I Saleh; Sameh Alzubiedi
Journal:  Mol Diagn Ther       Date:  2014-06       Impact factor: 4.074

5.  Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis.

Authors:  Edith A Nutescu; Cathy M Helgason
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-07

Review 6.  The role of osteocalcin in human glucose metabolism: marker or mediator?

Authors:  Sarah L Booth; Amanda Centi; Steven R Smith; Caren Gundberg
Journal:  Nat Rev Endocrinol       Date:  2012-11-13       Impact factor: 43.330

Review 7.  Warfarin therapy: in need of improvement after all these years.

Authors:  Stephen E Kimmel
Journal:  Expert Opin Pharmacother       Date:  2008-04       Impact factor: 3.889

8.  Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Authors:  Luis Almeida; Amílcar Falcão; Manuel Vaz-da-Silva; Teresa Nunes; Ana-Teresa Santos; José-Francisco Rocha; Carla Neta; Tice Macedo; C Fontes-Ribeiro; P Soares-da-Silva
Journal:  Eur J Clin Pharmacol       Date:  2008-08-06       Impact factor: 2.953

Review 9.  Bilateral spontaneous hyphaema: case report and review of literature.

Authors:  Aruna Dharmasena; Gillian M Watts
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

Review 10.  Clinically relevant drug interactions with antiepileptic drugs.

Authors:  Emilio Perucca
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.